Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Nom du journal : The Lancet Oncology
Année : 2021
Volume : 22
Page de départ : 1721
Page de fin : 1731